Global Barretts Esophagus Market, By Drug Class (Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Mucosal Protective Agents, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America,

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	180 Pages	Coherent Market Insights	March, 2024	CMI18685466

Best Price Guarantee
Price	from $4,500
Length	180 Pages
Publisher	Coherent Market Insights
Published Date	March, 2024
SKU	CMI18685466

Global Barretts Esophagus Market, By Drug Class (Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists, Mucosal Protective Agents, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Barrett's esophagus is a condition where the lining of the esophagus is damaged due to chronic acid reflux. It is a serious complication of gastroesophageal reflux disease (GERD) where the lining of the esophagus is replaced by the abnormal tissue similar to the lining of the intestine. This change in the cells of the esophagus can increase the chances of developing esophageal adenocarcinoma, a type of esophageal cancer. Barrett's esophagus usually does not cause symptoms but can be diagnosed by esophagogastroduodenoscopy (EGD) along with biopsy. The key predisposing factor is chronic GERD where stomach acid damages the esophagus over many years. Other risk factors include obesity, smoking, and male gender. The condition needs to be closely monitored as it is a precursor to esophageal cancer. Treatment involves lifestyle modifications and medication to control acid reflux. In some cases, radiofrequency ablation or endoscopic mucosal resection may be recommended to remove dysplastic tissues.

Market Dynamics:

Global Barrett’s esophagus market growth is driven by increasing prevalence of gastroesophageal reflux disease (GERD) and obesity rates worldwide. Chronic and untreated GERD are major risk factors for Barrett’s esophagus. According to the National Institute of Diabetes and Digestive and Kidney Diseases Report published in 2020, approximately 60 million Americans experience heartburn at least once a month. Obesity is another important factor predisposing to GERD due to excess pressure on the abdomen. The market also stands to benefit from routine screening practices for esophageal cancer. However, the market growth can be restrained by the asymptomatic nature of Barrett’s esophagus leading to underdiagnoses in some cases. Lack of approved drugs for the treatment and high cost of management procedures also challenges the market to some extent. Nevertheless, ongoing research on novel diagnostic biomarkers and therapeutic strategies present lucrative opportunities in the long run.

Key Features of the Study:

This report provides an in-depth analysis of the global Barrett’s esophagus market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Barrett’s esophagus market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include AstraZeneca, Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Sanofi, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, AbbVie Inc., Ferring Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Barrett’s esophagus market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Barrett’s esophagus market

Detailed Segmentation:

By Drug Class:
Proton Pump Inhibitors (PPIs)
H2 Receptor Antagonists
Mucosal Protective Agents
Others (Endoscopic Therapy Drugs, etc.)
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles:
AstraZeneca
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Novartis International AG
Sanofi
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Reddy's Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Lupin Limited
AbbVie Inc.
Ferring Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.

1. Research Objectives and Assumptions: Research Objectives; Assumptions
2. Market Overview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug Class; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Market Scenario - Conservative, Like, Opportunistic; Market Opportunity Map
3. Market Dynamics: Market Dynamics; Drivers; Restraints; Opportunities; Impact Analysis; Pest Analysis; Porters Analysis; Technological Advancement; Merger, Acquisition and Collaboration Scenario; Recent Product Approvals; Regulatory Scenario
4. Global Barrett’s Esophagus Market, By Drug Class, 2019 – 2031, (US$ Billion): Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Segment Trends; Proton Pump Inhibitors (PPIs), 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); H2 Receptor Antagonists, 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Mucosal Protective Agents, 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Others (Endoscopic Therapy Drugs, etc.), 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion)
5. Global Barrett’s Esophagus Market, By Distribution Channel, 2019 – 2031, (US$ Billion): Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Segment Trends; Hospital Pharmacies, 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Retail Pharmacies, 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion); Online Pharmacies, 2019 – 2031, (US$ Billion); Introduction; Market Size and Forecast, 2019 - 2031, (US$ Billion)
6. Global Barrett’s Esophagus Market, By Region, 2019 – 2031, (US$ Billion): Introduction; Market Share Analysis, 2024 - 2031, (US$ Billion); Segment Trends; By Region; North America; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion); U.S.; Canada; Europe; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Latin America; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Middle East; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country, 2019 - 2031, (US$ Billion); GCC; Israel; Rest of The Middle East; Africa; Introduction; Market Size and Forecast, By Drug Class, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Distribution Channel, 2019 - 2031, (US$ Billion); Market Size and Forecast, By Country/Region, 2019 - 2031, (US$ Billion); South Africa; North Africa; Central Africa
7. Company Profiles - Global Barrett’s Esophagus Market: AstraZeneca*; Company Overview; Product/Service Portfolio; Financial Performance; Recent Developments/Updates; Strategic Overview; Takeda Pharmaceutical Company Limited; Pfizer Inc.; Novartis International AG; Sanofi; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Sun Pharmaceutical Industries Ltd.; Lupin Limited; AbbVie Inc.; Ferring Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.
8. References and Research Methodology: References; Research Methodology; About us and Sales Contact